SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

$HYPR
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Get the next $HYPR alert in real time by email
SC 13G/A 1 p22-0442sc13ga.htm HYPERFINE, INC

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13G/A
 
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
 

Hyperfine, Inc.

(formerly known as HealthCor Catalio Acquisition Corp.)

(Name of Issuer)
 

Class A Common Stock, $0.0001 par value per share

(Title of Class of Securities)
 

44916K106

(CUSIP Number)
 

December 31, 2021

(Date of Event Which Requires Filing of This Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
¨ Rule 13d-1(b)
ý Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 8 Pages)

 

______________________________

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 44916K10613G/APage 2 of 8 Pages

 

1

NAMES OF REPORTING PERSONS

Empyrean Capital Overseas Master Fund, Ltd.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ý

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.0%

12

TYPE OF REPORTING PERSON

CO

         

 

 

CUSIP No. 44916K10613G/APage 3 of 8 Pages

 

1

NAMES OF REPORTING PERSONS

Empyrean Capital Partners, LP

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ý

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.0%

12

TYPE OF REPORTING PERSON

PN

         

 

 

 

CUSIP No. 44916K10613G/APage 4 of 8 Pages

 

1

NAMES OF REPORTING PERSONS

Amos Meron

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ý

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.0%

12

TYPE OF REPORTING PERSON

IN

         

 

 

 

CUSIP No. 44916K10613G/APage 5 of 8 Pages

 

Item 1(a). NAME OF ISSUER.
   
  The name of the issuer is Hyperfine, Inc. (formerly known as HealthCor Catalio Acquisition Corp.) (the "Issuer").

 

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
   
  The Issuer's principal executive offices are located at 351 New Whitfield Street, Guilford, Connecticut 06437.

 

Item 2(a). NAME OF PERSON FILING:

 

  This statement is filed by:

 

  (i) Empyrean Capital Overseas Master Fund, Ltd. ("ECOMF"), a Cayman Islands exempted company, with respect to the Class A Common Stock (as defined in Item 2(d)) directly held by it;
   
  (ii) Empyrean Capital Partners, LP ("ECP"), a Delaware limited partnership, which serves as investment manager to ECOMF with respect to the Class A Common Stock directly held by ECOMF;
   
  (iii) Mr. Amos Meron, who serves as the managing member of Empyrean Capital, LLC, the general partner of ECP, with respect to the Class A Common Stock directly held by ECOMF.

 

  The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
   
  The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of Class A Common Stock owned by another Reporting Person.

 

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

 

  The address of the business office of each of the Reporting Persons is c/o Empyrean Capital Partners, LP, 10250 Constellation Boulevard, Suite 2950, Los Angeles, CA 90067.

 

Item 2(c). CITIZENSHIP:

 

  ECOMF - a Cayman Island exempted company
  ECP - a Delaware limited partnership
  Amos Meron - United States

 

Item 2(d). TITLE OF CLASS OF SECURITIES:
   
  Class A common stock, $0.0001 par value per share (the "Class A Common Stock")

 

 

CUSIP No. 44916K10613G/APage 6 of 8 Pages

 

Item 2(e). CUSIP NUMBER:
   
  44916K106

 

Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

 

  (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
  (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
  (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
  (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
  (e) ¨ Investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
  (f) ¨

Employee benefit plan or endowment fund in accordance with

§ 240.13d-1(b)(1)(ii)(F);

 

  (g) ¨

Parent holding company or control person in accordance with

§ 240.13d-1(b)(1)(ii)(G);

  (h) ¨

Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

  (i) ¨

Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

 

  (j) ¨ Non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

 

 

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please

specify the type of institution:                                                                                         

 

Item 4. OWNERSHIP.

 

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

 

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

 

 

CUSIP No. 44916K10613G/APage 7 of 8 Pages

 

Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
   
  Not applicable.

 

Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
   
  Not applicable.

 

Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
   
  Not applicable.

 

Item 9. NOTICE OF DISSOLUTION OF GROUP.
   
  Not applicable.

 

Item 10. CERTIFICATION.

 

  Each of the Reporting Persons hereby makes the following certification:
   
  By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

CUSIP No. 44916K10613G/APage 8 of 8 Pages

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

DATED:  February 10, 2022  
   
  empyrean capital partners, lp
   
  By: /s/ C. Martin Meekins
  Name: C. Martin Meekins
  Title: Chief Operating Officer
   
   
  Empyrean Capital Overseas MASTER Fund, Ltd.
  By: Empyrean Capital Partners, LP,
  its Investment Manager
   
  By: /s/ C. Martin Meekins
  Name: C. Martin Meekins
  Title: Chief Operating Officer
   
  /s/ Amos Meron
  AMOS MERON
       

 

 

Get the next $HYPR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HYPR

DatePrice TargetRatingAnalyst
8/11/2022$8.00 → $2.40Overweight → Equal Weight
Wells Fargo
5/31/2022$7.00Outperform
Evercore ISI
4/14/2022$8.00Overweight
Wells Fargo
More analyst ratings

$HYPR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

    GUILFORD, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2024 financial results and provided a business update. "I am pleased with the many milestones we achieved in the fourth quarter of 2024. These set the stage well for us to execute on our expansion plan, drive accelerated growth across multiple sites of care globally and meaningfully reduce cash burn in 2025," said Maria Sainz, Chief Executive Officer and President of Hyperfine,

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Hyperfine and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation

    Collaboration aims to make portable MRI faster, smarter, and more accessible worldwide. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced a strategic collaboration with NVIDIA. This collaboration leverages NVIDIA AI expertise and accelerated computing to enhance Hyperfine portable imaging technology—making brain MRI faster, smarter, and more affordable on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317452571/en/The AI-powered

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$HYPR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HYPR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HYPR
SEC Filings

See more

$HYPR
Leadership Updates

Live Leadership Updates

See more
  • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    $CTLT
    $HYPR
    $NVST
    $QDEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments
  • Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

    Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

    Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$HYPR
Financials

Live finance-specific insights

See more
  • Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Hyperfine, Inc. Reports Third Quarter 2024 Financial Results

    GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update. "The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally," said Maria Sainz, Chief Executive Officer and President of Hy

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the third quarter 2024 on Tuesday, November 12, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About th

    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$HYPR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more